<c) (f) and (g) Prices of finished vaccines are controlled under the DPCO. Details will be comuiled and laid on the table of the House. Tho DPCO hag moderated the prices of vaccineb. «

(d) and (e) Information to the extent available is given in the Annexure.

Annexure

I Prodution

Year	Production	
	Anti Gas Gengrene vaccine (Ltrs.)	Anti Rabbies Vaccine (K. Ltrs.)
1982-83	14.00	5.95
1983-84	29.00	6.37
1984-85	5.00	5.30

II Imports

Item	Import (Doses)		
	1982-83	1983-84	1984-85
1. Poliomyelitis vaccine (Inactivated)	Nil	20,000	Nil
2. Poliomyelitis Vaccine Trivalent (Oral)	3066000	161750	7252280
3. Poliomyelitis Vaccine (Monovalent)	41000000	35000000	52500000

Production of Drugs

840. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to state:

(a) names of the drugs under category I and II of existing Drugs Price Control Order 1979 for which production has fallen from the inception of Price Control Order, 1979.

(b) what was the production of each of these drugs during 1978 and 1985 and what is the percentage of fall in each case;

(c) names of the producers who are licensed to produce these drugs alongwith name, licenced and installed capacity and production of each drug during the last three years, year-wise; and

(d) names of formulations and drugs which fall under exempted category being produced by these companies and what was the production of Bulk Drugs and sales turn-over of formulations during 1978 and 1985 separately?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Among the monitored category I and II bulk drugs the production of Dapsone, Di-iodohydroxyquinoline, Iodochlorohydroxy quinoline, PAS and its Salts, Penicillin, Amodiaquin, Analgin, Phenobarbitone and Sulphadimidine was

lower in 198485, in 1984-85, in comparison with 1979-80.

(b) and (c) Details to the extent available, are given in Annexure I and H.

(d) Sales turn-over of formulations is not monitored. Other detail to the extent available, will be collected and laid on the table ofthe House.

l

Annexure—I

Sl. No.	Name of the Drug	A/C Unit	Production 1978-79	Production 1984-85	Percentage variation in production
1	Dapsone	T	18.05	7.25	(—) 59.8
2	Di-iodohydroxy Quinoline	T	9.91	3.22	(—) 67.5
3	Idochlorohydroxy Quinoline	T	142.68	151.10	(+) 5.9
4	PAS & Its Salts	T	601.46	119.07	(—) 80.2
5	Penicillin	MNU	319.95	221.68	(—) 30.7
6	Amodiaquin	T	29.00	26.41	(—) 28.9
7	Analgin	T	277.79	335.87	(+) 20.9
8	Phenobarbitone	T	20.53	5.09	(—) 75.2
9	Sulphasalazine	T	375.18	313.60	(—) 16.4

Annexure—II

Name of drug/Manufacturing Unit	A/c Unit	Licensed Capacity	Production 1982-83	Production 1983-84	Production 1984-85
I. Dapsone	T				
(i) B.C.P.L.		15.00	7.58	6.05	2.75
(ii) Burroughs-Wellcome		28.00	23.36	22.92	4.43
(iii) Tuber Pharma		..	..	0.30	0.07
II. Di-Iodohydroxy Quinoline	T				
(i) Albert David		$	4.17	4.63	3.22
III. Iodochlorohydroxy Quinoline	T				
(i) Albert David		1.25	6.18	5.84	11.47
(ii) Atul		170.00	140.40	54.78	69.28
(iii) E.I.P.W.		212.00	52.42	57.15	65.91
(iv) Bio-Evans		12.00	..	..	4.44

1	2	3	4	5	6	
IV. Pas and ITS Salts		T				
	(i) I.D.P.L.		400.00	102.30	114.55	29.15
	(ii) Biochem Synth		100.00	104.40	77.31	76.15
	(iii) Pfizer		110.00	12.60	3.67	8.52
	(iv) Wander		300.00	26.60	21.46	5.25
V. Penicillin		MMU				
	(i) I.D.P.L.		230.00	58.52	55.60	34.20
	(ii) H.A.L.		160.00	72.21	69.02	69.94
	(iii) Alembic		100.00	101.19	84.60	52.53
	(iv) Standard Pharma		147.00	126.45	107.52	65.01
VI. Amodiaquin		T				
	(i) Parke-Davis		36.00	20.53	7.86	5.12
	(ii) Suncela Chem.		30.00	9.62	15.55	21.29
VII. Analgin		T				
	(i) I.D.P.L.		400.00	239.20	314.71	335.87
VIII. Phenobarbitone		T				
	(i) I.D.P.L.		30.00	29.40	12.86	5.09
IX. Sulphadimidine		T				
	(i) I.D.P.L.		1000.00	513.25	480.60	313.60

.$: Combined'Capacity with Iodo-C&lorofaydroxyquinnliiw-.

Production of Steriods

841. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to state:

(a) name$_s$ of the companies which are licenced to .produce Steriods and cartico-steriodg from basic stages alongwith the name of each drug falling under this category;

(b) whether it is a fact that these companies, instead of producing from basic stages are producing from imported and locally procured imported penultimates/intermediates;

(c) what is th$_e$ quantity of each imported penultimate and intermedlat procured locally and imported by each manufacturer during the last three years$_i$ year-wise.

(d) whether it is a fact that on the one side the capacities are lying idle for production of intermediates {penultimates and on other side huge foreign exchange is being; wastert; and

(e) what are the reasons for not monitoring such imports by the Department?

THE MINISTER OF STATE IN THE DEPARTMENT *OF* CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) M|s. Glaso and M's. Wyeth are licensed to